Please provide your email address to receive an email when new articles are posted on . ANAHEIM, Calif. — Left main coronary bifurcation intervention with drug-eluting stent implantation showed ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
Among 484 patients randomly assigned to DK crush stenting or provisional stenting, the respective rates of TLF (a composite of cardiac death, target vessel MI, and/or target lesion revascularization) ...
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Advanced Bifurcation Systems (ABS), a clinical-stage medical device company with a patented bifurcation stenting platform to standardize the treatment of all ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The double kissing crush two-stent ...
A systematic two-stent approach to complex coronary bifurcation lesions led to significantly improved clinical outcomes at 1 year, compared with the long-popular provisional stenting technique, in the ...
New data demonstrated that a left main (LM) bifurcation-specific novel scoring system (LM V-RESOLVE), based on three simple baseline angiographic findings, could help to rapidly discriminate lesions ...
Long Beach, Calif. – May 2, 2024 – New data demonstrated that a left main (LM) bifurcation-specific novel scoring system (LM V-RESOLVE), based on three simple baseline angiographic findings, could ...
Medtronic recently announced the FDA approval of the Onyx Frontier drug-eluting stent (DES) and the Resolute Onyx DES for the treatment of non-left main bifurcation lesions. “The Onyx Frontier and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback